US OptionsDetailed Quotes
NBIX250516P180000
- 0.00
- 0.000.00%
15min DelayClose Apr 30 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest180.00Strike Price0.00Turnover133.94%IV-67.15%PremiumMay 16, 2025Expiry Date72.31Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9597Delta0.0034Gamma1.48Leverage Ratio-0.0673Theta-0.0394Rho-1.42Eff Leverage0.0192Vega
Neurocrine Biosciences Stock Discussion
Breakthrough Schizophrenia Treatment Enters Final Testing Phase with Promising 18-Point Symptom Reduction
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate
Breakthrough: INGREZZA Achieves 59% Remission in Tardive Dyskinesia Patients Over 48 Weeks
Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions
Can Neurocrine's New VMAT2 Inhibitor Replicate Its Previous FDA Success? Phase 1 Trial Launches
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded down 0.95%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.99%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 1.36%.
MACRO
Macroeconomic news might have swayed the market as jobs and unemployment data came in. The economy added 143,000 jobs in January, according to the BLS, which was low, but N...
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
Who led the selloff. Come on man 🚀🚀🚀
No comment yet